NewswireToday - /newswire/ -
Ludwigshafen, Rhineland-Palatinate, Germany, 2021/05/07 - On April 26, 2021 BASF has agreed with Sandoz GmbH, a subsidiary of Novartis, to invest at the Kundl/Schaftenau Campus in Austria - Sandoz.com / Novartis.com / Care-Chemicals.BASF.com. DE000BASF111
• BASF will invest at Novartis’ Kundl/Schaftenau Campus, in Austria;
• Target is to further develop a world-scale production set-up for bacterial enzymes and biotechnology products;
• With this investment, BASF strengthens its position in the enzymes and biotechnology market.
This agreement enables BASF to further develop its production footprint for enzymes and biotechnology products.
Both parties agreed not to disclose financial details of the agreement.
“This investment is a clear sign of our commitment to the enzymes and biotechnology industry. BASF will strengthen its position in the market, as the Kundl/Schaftenau Campus has 75 years of biotechnology practice and corresponding infrastructure, including deep know-how,” said Dr. Michael De Marco, Vice President Global Business Management Enzymes for BASF.
“The agreement enables us to expand our production footprint for detergent enzymes and further enhance our product portfolio and leading market position in the Home Care and I&I industry,” said Dr. Soeren Hildebrandt, Senior Vice President Home Care, I&I and Industrial Formulators Europe. “With this step we support our customers to address key market needs such as cleaning products with superior sustainability profiles and new product formats, based on innovative BASF enzyme technology.”
"Tyrol is a key location for our global production network. Our investments in Kundl and Schaftenau reinforce our commitment to the region," says Steffen Lang, Head of Novartis Technical Operations and member of the Novartis Executive Committee. "With the further development into a Life Science Park and the settlement of BASF, an important player in the field of biotechnology, we are strengthening the competence and innovation capacity of the area."
BASF seeks also to explore the potential to grow further via deeper involvement in the Kundl/Schaftenau Campus. The start of production is planned for 2024.
About BASF’s Nutrition & Health division
BASF Nutrition & Health provides a comprehensive product and service range for human and animal nutrition, pharmaceutical, bioenergy and flavor & fragrance industries. With our science-driven portfolio, we address customers in globally growing markets to meet the demands of an expanding world population. Together with our customers, we play an active role in enhancing the nutrition, health and wellbeing of consumers all over the world. Our products fulfill the highest safety, regulatory and sustainability standards. BASF Nutrition & Health operates sites in Europe, North America, South America and in Asia-Pacific.
About BASF’s Care Chemicals division
BASF Care Chemicals (care-chemicals.basf.com) offer a broad range of ingredients for personal care, home care, industrial & institutional cleaning, and technical applications. We are a leading global supplier for the cosmetics industry as well as the detergent and cleaner industry, and support our customers with innovative and sustainable products, solutions and concepts. The division’s high-performance product portfolio includes surfactants, emulsifiers, polymers, emollients, chelating agents, cosmetic active ingredients and UV filters. We have production and development sites in all regions and are expanding our presence in emerging markets.
At BASF (basf.com), we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 110,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €59 billion in 2020.
Novartis (novartis.com) is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.